Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.
CONCLUSION: A significant subset of patients with mPDAC can achieve long-term survival (≥18 months) in 2018. We identified low NLR as a significant prognostic factor associated with long-term survival in mPDAC.
IMPLICATIONS FOR PRACTICE: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is one of the most lethal types of cancer. A subset of patients with mPDAC can achieve long-term survival (≥18 months) with a modern chemotherapy regimen, such as FOLFIRINOX or gemcitabine/nab-paclitaxel. We identified low neutrophil-to-lymphocyte ratio (NLR) as a significant prognostic factor associated with long-term survival in mPDAC. Prognostic factors such as NLR might allow accurate selection of patients with mPDAC in order to consider individual therapeutic approaches. NLR should be used as a stratification factor in clinical trials.
PMID: 31164454 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Rochefort P, Lardy-Cleaud A, Sarabi M, Desseigne F, Cattey-Javouhey A, de la Fouchardière C Tags: Oncologist Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | France Health | Hepatocellular Carcinoma | Liver | Liver Cancer | Pancreas | Pancreatic Cancer | Peritoneal Cancer | Study | Urology & Nephrology | Women